Life

Pharma companies and patient groups seek to exempt orphan drugs from Colorado pricing limits

Strategic angle: A bill is moving through the Colorado legislature that would exempt orphan drugs from pricing caps that might be pursued by the state.

Global Health Funding in the FY 2027 President’s Budget Request

Strategic angle: This budget summary provides an analysis of global health funding amounts provided in the President's FY 2027 budget request.

California's Medicaid Work Requirements Amid Budget Shortfalls

Strategic angle: Examining the state's plans to implement work requirements in Medicaid while facing significant budget challenges.

STAT+: A key Medicare Advantage announcement is due today

Strategic angle: Today's announcement will set the tone for how the Trump administration wants to work with private Medicare insurers.

How a four-month FDA delay forced a small biotech company to close its doors

A small biotech company faced a critical setback due to a delayed agreement with the FDA, leading to its closure.

Stealth biotech Stipple bets on secretive ADCs

Strategic angle: How thin science fuels peptide hype, blowback to proposed NIH cuts, and more biotech news from The Readout

UnitedHealth makes a bet on AI. What does it mean for us?

Strategic angle: A hep B trial raises ethical questions, the peptide hype, and more Morning Rounds news

Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal

Strategic angle: Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion, gaining access to a treatment for a rare disease linked to insatiable hunger.

Opinion: ‘Medical nutrition’ helps keep my son, and many others, healthy. But insurance won’t cover it

Strategic angle: Lifelong disorders require lifelong treatments.

Opinion: When my child is in psychosis, the pediatric health care system can’t help us

Strategic angle: “There is no off switch when the crisis is your child,” writes Liz Koch.

Briefing: UnitedHealth Group is making a $3 billion bet on AI. What does it mean for patients?

Strategic angle: UnitedHealth Group is rapidly deploying artificial intelligence tools across its operations. What does it mean for patients?

What the peptide craze reveals about Americans’ relationship with risk

Strategic angle: Why do RFK Jr. and other health influencers embrace unproven peptides while calling for more research into well-studied vaccines?

Briefing: NIH Faces $5 Billion Cut in Trump's 2027 Budget Proposal

Strategic angle: Congress is expected to resist the proposed reduction in funding for the National Institutes of Health.

Briefing: White House Proposes 12% Cut to Federal Health Agencies in 2027 Budget Request

Strategic angle: The proposal comes as Congress previously ignored similar cuts, opting instead to increase health spending.

Briefing: STAT+: Up and down the ladder: The latest comings and goings

Strategic angle: From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Briefing: Biotech Investors Urge Trump Amid M&A Activity

Strategic angle: Smaller biotechs negotiate with the White House while addressing the trust gap in medicine.

Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts

The taxes are part of the president's push to rein in the pharmaceutical industry and bring manufacturing to the U.S.

Briefing: Thursday was World Autism Awareness Day. HHS celebrated with…a workout?

Strategic angle: Implications of SCOTUS' conversion therapy ruling, Trump hikes drug tariffs, and more Morning Rounds updates

Briefing: Opinion: My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine

Strategic angle: “The volume of evidence behind a therapy has become inversely correlated with public trust in it,” writes Vikas Patel.